Discover MabDesign
MabDesign, the French association of the industrial sector of biomedicines, aims to support, structure, federate and increase the visibility of the industrial sector of biological medicines.

Access our network
Join the MabDesign network to take advantage of all the advantages and opportunities offered.

Develop your skills
Consult and register for our next training courses in order to acquire new expertise.

Explore our business services
The field of therapeutic antibodies and immunotherapy is growing rapidly. The French industrial ecosystem is rich in innovative companies with considerable potential. MabDesign’s mission is to support them in their development in France and abroad.

Upcoming events
Add your title here
30
Jun.
30 June - 1 Juli 2026
Partner Event
30
Jun.
June, 30 - July 1, 2026
Mabdesign Event
08
Sep.
Septembre 8-9, 2026
Partner Event
22
Sep.
September 22-23 2026
Mabdesign Event
29
Sep.
29 September -1 October 2026
Partner Event
08
Oct.
8-9 October 2026
Partner Event
Our News

Les maladies inflammatoires chroniques de l'intestin
3 June 2026
Les analyses de marché de MabDesign vous proposent chaque mois un aperçu des dynamiques du marché et des projets en développement pour une indication ou une technologie donnée, afin de mieux appréhender le marché en constante évolution des biomédicaments et de la bioproduction. Ce mois-ci, un aperçu du marché et des projets actuellement en développement pour le traitement des maladies inflammatoires chroniques de l’intestin (MICI).

chronic inflammatory bowel diseases
3 June 2026
MabDesign’s market analyses give you a monthly overview of market dynamics and projects in development for a given indication or technology, to help you better understand the constantly evolving market of biologics and biomanufacturing. This month, an overview of the market and projects currently under development for the treatment of inflammatory bowel diseases (IBD).

ZOOM ON - G-CLips
28 May 2026
G.CLIPS Biotech, a technology platform company, changing the paradigm on targets by enabling the discovery, generation and validation of conformation-sensitive and pathology-sensitive drug candidates.
We accelerate, advance, and derisk your drug development path since early discovery stages.

Myonex triple ses capacités de conditionnement primaire de produits hautement actifs et cytotoxiques en France
19 May 2026
Myonex annonce l’extension de ses capacités de conditionnement primaire avec l’autorisation de réaliser sur son site du Haillan, en France, des opérations de conditionnement primaire sous BPF (Bonnes Pratiques de Fabrication) pour des produits pharmaceutiques hautement actifs et dangereux, incluant des composés cytotoxiques et hormonaux.
OUR BOARD OF DIRECTORS








































































































































































































































































































































































































